The selection of contract manufacturing organizations for Tonmya and the planned NDA submission are significant steps towards commercialization. This news is likely to be viewed positively by investors as it demonstrates progress in the development and potential market entry of Tonmya for fibromyalgia treatment. The direct involvement in the manufacturing and regulatory submission process increases the relevance and importance of this news for Tonix Pharmaceuticals.